Anthem Biosciences Ltd (ANTHEM)
₹828.80
Mkt cap
₹46,689 Cr
P/E ratio
78.70
P/B
15.29
Div yield
0.24%
ROE
22.30%
ROCE
30.40%
EPS (TTM)
₹10.53
Book value
₹54
52W range
579–978
Sector
Healthcare
Price history
Previous close
Incorporated in 2006, Anthem Biosciences Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients. [1]
NSE ANTHEMBSE 544449
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−15.22% from high₹829
₹579+43.11% from low₹978
Current
₹828.80
Prev close
₹830.15
Day
−0.16%
Price performance
1D
−0.03%
1W
+2.10%
1M
−4.58%
3M
+5.80%
6M
+7.05%
1Y
+15.62%
YTD
+26.64%
Financials
Revenue, profit & margin
P/E ratio
78.7×
ANTHEM is 63% above the sector median of 48.4×
ANTHEM78.7×
Sector median48.4×
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 339 | 525 | 498 | 483 | 540 | 550 | 423 | 611 | 418 | |
| Expenses | 218 | 330 | 338 | 288 | 349 | 332 | 266 | 344 | 268 | |
| Operating Profit | 121 | 195 | 160 | 195 | 191 | 218 | 157 | 267 | 151 | |
| OPM % | 36% | 37% | 32% | 40% | 35% | 40% | 37% | 44% | 36% | |
| Other Income | 19 | 28 | 24 | 14 | 23 | 48 | 8 | 52 | 25 | |
| Interest | 4 | 4 | 3 | 1 | 2 | 3 | 0 | 2 | 1 | |
| Depreciation | 19 | 20 | 20 | 30 | 26 | 34 | 35 | 40 | 30 | |
| Profit before tax | 118 | 200 | 161 | 178 | 186 | 230 | 130 | 278 | 145 | |
| Tax % | 30% | 19% | 23% | 54% | 27% | 24% | 29% | 32% | 17% | |
| Net Profit | 82 | 162 | 124 | 83 | 136 | 173 | 93 | 190 | 120 | |
| EPS in Rs | 1.47 | 2.90 | 2.22 | 1.48 | 2.42 | 3.09 | 1.65 | 3.38 | 2.13 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
3 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +2.58% · closed higher next day 2 of last 5
| Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26† | Q1FY27 | |
|---|---|---|---|---|---|
| Broadcast | 13 Aug '25◦ | 9 Nov '25◦ | 5 Feb '26 | 20 May '26◦ | 21 Jul '26◦ |
| Earnings day | +9.27% | +1.21% | +4.91% | −0.87% | −1.60% |
| +1 day | +6.05% | −2.29% | +7.86% | −2.32% | −1.73% |
| +5 days | +9.00% | −4.46% | +16.21% | −3.83% | −0.20% |
| +15 days | +8.10% | −5.33% | +16.22% | −0.93% | +10.97% |
| +30 days | +1.44% | −2.17% | +6.53% | −2.09% | +18.06% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 2 Per Share | 2.00 | 25 Jun '26 | 26 Jun '26 |
Shareholding
as of Sep 202671.39%Promoter
Promoters71.39%0.03
FIIs3.79%1.22
DIIs12.10%1.38
Public12.71%0.19
Ownership trend
Peers
6 companies| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Anthem Bioscienc | ₹828.80 | 78.69 | 46,689 | 0.24% | 120 | −11.67% | 418 | −22.58% | 30.37% |
| Advanced Enzyme | ₹263.55 | 18.15 | 2,951 | 2.03% | 51 | +11.49% | 215 | +16.25% | 13.96% |
| CCME Global | ₹33.55 | — | 152 | 0.00% | 0 | −116.67% | 0 | — | −2.92% |
| Vivo Bio Tech | ₹13.72 | — | 30 | 0.00% | 0 | −85.82% | 14 | +14.15% | 7.74% |
| Shree Ganesh Bio | ₹0.43 | — | 17 | 0.00% | −1 | −272.73% | 1 | +3.62% | 1.31% |
| Genomic Valley | ₹48.10 | — | 15 | 0.00% | 0 | — | 0 | −100.00% | 1.02% |
| Median: 3 Co. | ₹263.55 | 48.42 | 2,951 | 0.24% | 51 | −11.67% | 215 | −3.16% | 13.96% |
Filings
Annual reports2
Concall transcripts16
Credit ratings2
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 30 Oct - Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2026Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026 28 Oct - Board meeting on November 3, 2026 to consider Q2 and half-year FY26 financial results; trading window closed until November 5.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Oct - Submitted Regulation 74(5) depository certificate for quarter ended September 30, 2026.Closure of Trading Window 24 SepSettlement Of Upside Sharing Arrangement 8 Sep - Settlement of upside sharing arrangement; INR 1,276.83 million paid to three principal shareholders after Viridity Tone LLP divestment.